Immune escape mechanisms in malignant melanoma (Review)

International Journal of Molecular Medicine

Volumn 3, Issue 1, 1999, Pages 49-57

  Geertsen, Ralf ^a,b   Hofbauer, Günther ^a   Kamarashev, Jivko ^a   Yue, Feng Yun ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Medica Diagnostic Laboratories   (Switzerland)

Author keywords

CTL; HLA; Malignant melanoma; TAA; TAP

Indexed keywords

HLA ANTIGEN; LEUKOCYTE ANTIGEN; MELANOMA SPECIFIC ANTIGENS; MELANOMA-SPECIFIC ANTIGENS; TUMOR PROTEIN;

GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; MELANOMA; REVIEW;

ANTIGENS, CD; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA ANTIGENS; HUMANS; MELANOMA; NEOPLASM PROTEINS;

EID: 0032614551     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Koh HK, Sinks TH, Geller AC, Miller DR and Lew RA: Etiology of melanoma. Cancer Treat Res 65: 1-28, 1993.
2. Haffner AC, Garbe C, Burg G, Buttner P, Orfanos CE and Rassncr G: The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br J Cancer 66: 856-861, 1992.
3. Lcgha SS: Current therapy for malignant melanoma. Semin Oncol 16: 534-344, 1989.
4. Garbe C, Kreuser ED, Zouboulis CC, Stadier R and Orfanos CE: Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Semin Oncol 19: S63-S69, 1992.
5. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS and Hunstein W: Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials Cancer 72: 607-614, 1993.
6. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC and Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncolosy Group Trial EST 1684. J Clin Oncol 14: 7-17, 1996.
7. Dummer R, Gore M, Hancock B, Guillou P, Grobben H, Becker J, Oskam R, Dieleman J and Burg G: A multicenter phase II clinical trial using dacarbazine and continuous infusion of interleukin-2 in metastatic melanoma: clinical data and immunomonitorinc. Cancer 75: 1038-1044, 1995.
8. Falkson CI, Falkson G and Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malicnant melanoma. J Clin Oncol 9: 1403-1408, 1991.
9. Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S and Rosenberg SA: Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 53: 5-8, 1993.
10. Bakker AB, Schreurs MW, De BA, Kawakami Y, Rosenberg SA, Adema GJ and Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumorinfiltrating lymphocytes. J Exp Med 179: 1005-1009, 1994.
11. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T and Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91: 3515-3519, 1994.
12. Wolfel T, van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH and Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24: 759-764, 1994.
13. Wang RF, Appella E, Kawakami Y, Kang X and Rosenberg SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184: 2207-2216, 1996.
14. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, et al: Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153: 1225-1237, 1994.
15. Ferrone S and Marincola FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494, 1995.
16. Van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K and Ferrone S: Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48: 1019-1025, 1988.
17. Garrido F, Ruiz-Caballo F, Cabrera T, Pérez-Villar JJ, Lopez-Botet M, Duggan-Keen M and Stern PL: Implications for immunosurveillance of altered HLA-class I phenotypes in human tumors. Immunol Today 18: 89-95, 1997.
18. D'Urso CM, Wang ZG, Cao Y, Tatakc R, Zcff RA and Ferrone S: Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 87:284-292, 1991.
19. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A and Ferrone S: Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest 91: 684-692, 1993.
20. Maio M, Altomonte M, Tatake R, Zeff RA and Ferrone S: Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 88: 282-289, 1991.
21. Versteeg R: NK cells and T cells: mirror imaces? Immunol Today 13: 244-247, 1992.
22. Cromme FV, van Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Heimerhorst TJ, Stukart MJ and Meijer CJ: Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 69: 1176-1181, 1994.
23. Kcating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD, Dyer PA and Stern PL: Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72: 405-411, 1995.
24. Thor Strafen P, Kirkin AF, Seremet T and Zeuthen J: Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int J Cancer 70: 582-586, 1997.
25. Kageshita T, Wang Z, Calorini L, Yoshii A, Kimura T, Ono T, Gattoni-Celli S and Ferrone S: Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 53: 3349-3354, 1993.
26. Luboldt HJ, Kubens BS, Rubben H and Grosse-Wilde H: Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56: 826-830, 1996.
27. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, et al: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55: 3149-3157, 1995.
28. Ruiter DJ, Mattijssen V, Broecker EB and Ferrone S: MHC antigens in human melanomas. Semin Cancer Biol 2: 35-45, 1991.
29. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM and Topalian SL: Comparative analysis of the in vivo expression of tyrosinase, Mart-1/Melan-a, and gp100 in metastatic melanoma lesions - implications for immunotherapy. J Immunother 21: 27-31, 1998.
30. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Stcinberg SM, Rosenberg SA and Marincola FM: Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75: 517-524, 1998.
31. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jäger D, Oesch F and Knuth A: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71: 142-147, 1997.
32. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183: 1965-1971, 1996.
33. Geertsen R, Hofbauer G, Yue F-Y, Burg G and Dummer R: Higher frequency of selective losses of HLA-A and -B allospecificities in metastases than in primary melanoma lesions. J Invest Dermatol 111: 497-502, 1998.
34. Griffioen M, Peltenburg LT, van Oorschot DA and Schrier PI: C-myc represses transiently transfected HLA class I promoter sequences not locus-specifically. Immunobiolocy 193: 238-247, 1995.
35. Brichard VG, Herman J, van Pel A, Wildmann C, Gaugier B, Wolfel T, Boon T and Lethe B: A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 26: 224-230, 1996.
36. Fleischhauer K, Fruci D, van Endert P, Herman J, Tanzarella S, Wallny HJ, Coulie P, Bordignon C and Traversari C: Characterization of antigcnic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int J Cancer 68: 622-628, 1996.
37. Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T and Coulie PG: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 43: 377-383, 1996.
38. Liischer U, Filgueira L, Juretic A, Zuber M, Lüscher NJ, Heberer M and Spagnoli GC: The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 57: 612-619, 1994.
39. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M and Knuth A: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66: 162-169, 1996.
40. Nestle FO, Alijagic S, Gilliet M, Sun YS, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
41. Groettrup M, Soza A, Kuckelkorn U and Kloetzel PM: Peptide antigen production by the proteasome: complexity provides efficiency. Immunol Today 17: 429-435, 1996.
42. Puhler G, Weinkauf S, Bachmann L, Muller S, Engel A, Hegerl R and Baumeister W: Subunit stoichiometry and three-dimensional arrangement in proteasomes from Thermoplasma acidophihun. EMBO J 11: 1607-1616, 1992.
43. Kopp F, Dahlmann B and Hendil KB: Evidence indicating that the human proteasome is a complex dimer. J Mol Biol 229: 14-19, 1993.
44. Brown MG, Driscoll J and Monaco JJ: Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 353: 355-357, 1991.
45. Tanaka K, Tanahashi N, Tsurumi C, Yokota KY and Shimbara N: Proteasomes and antisen processing. Adv Immunol 64: 1-38, 1997.
46. Driscoll J, Brown MG, Finley D and Monaco JJ: MHC-linkcd LMP gene products specifically alter peptidase activities of the proteasome. Nature 365: 262-264, 1993.
47. Bahram S, Arnold D, Brcsnahan M, Strominger JL and Spies T: Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II recion. Proc Natl Acad Sci USA 88: 10094-10098, 1991.
48. Colonna M, Bresnahan M, Bahram S, Strominger JL and Spies T: Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci USA 89: 3932-3936, 1992.
49. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, Pious D and De Mars R: A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 348: 744-747, 1990.
50. Townsend A and Trowsdale J: The transporters associated with antigen presentation. Semin Cell Biol 4: 53-61, 1993.
51. Rotem Yehudar R, Winograd S, Sela S, Coligan JE and Ehrlich R: Downregulation of peptide transporter genes in cell lines transformed with the hichly oncogenic adenovirus 12. J Exp Med 180: 477-488, 1994.
52. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL and Gatter KC: Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 73: 148-153, 1996.
53. Kaklamanis L, Townsend A, Doussis Anagnostopoulou IA, Mortensen N, Harris AL and Gatter KC: Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 145: 505-509, 1994.
54. Kaklamanis L, Leek R, Koukourakis M, Gatter KC and Harris AL: Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 55: 5191-5194, 1995.
55. Hicklin DJ, Kageshita T and Ferrone S: Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens 48: 38-46, 1996.
56. Gaugler B, van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F and Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921-930, 1994.
57. Bocl P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T and van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167-175, 1995.
58. Van den Eynde B, Peelers O, De Backer O, Gaugier B, Lucas S and Boon T: A new family of genes coding for an antigen recoenized by autolocous cytolytic T lymphocytes on a human melanoma. J Exp Med 182: 689-698, 1995.
59. Jaeger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ and Knuth A: Simultaneous humoral and cellular immune response against cancer-testis antigen Ny-Eso-1 - definition of human histocompatibility leukocyte antieen (Hla)-A2-bindins: peptide epitopcs. J Exp Med 187: 265-270; 1998.
60. Boon T, Coulie PG and van den Eynde B: Tumor antigens recognized by T cells. Immunol Today 18: 267-268, 1997.
61. Hofbauer G, Dummer R, Laine E and Burg G: Expression of melanoma-associated antigens in short-term melanoma cultures detected by RT-PCR and subsequent ELISA. Arch Dermatol Res 290: 458-461, 1998.
62. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M and Spagnoli GC: Identification and intracellular location of MAGE-3 gene product. Cancer Res 55: 2236-2239, 1995.
63. Hofbauer GFL, Schaefer C, Noppen C, Böni R, Kamarashcv J, Nestle FO, Spagnoli GC and Dummer R: Mage-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma - frequency and distribution. Am J Pathol 151: 1549-1553, 1997.
64. Wang RF, Robbins PF, Kawakami Y, Kang XQ and Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes (published erratum appears in J Exp Med 181: 1261, 1995). J Exp Med 181:799-804, 1995.
65. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA and Marincola FM: Enhancement of cellular immunity in melanoma patients immunized with a peptidc from MART-1/Melan A (see comments). Cancer J Sci Am 3: 37-44, 1997.
66. Chen YT, Stocken E, Tsang S, Coplan KA and Old LJ: Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 92: 8125-8129, 1995.
67. Hofbauer G, Kamarashcv J, Gecrtsen R, Böni R and Dummer R: Tyrosinase immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol 25: 204-209, 1998.
68. Hofbauer G, Kamarashcv J, Gcertsen R, Böni R and Dummer R: MelanA/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res 8: 337-343, 1998.
69. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y and Rosenberg SA: Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 19: 192-205, 1996.
70. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankein T, Meyer zum Buschenfelde KH and Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284, 1995.
71. Akslen LA, Monstad SE, Larsen B, Straume O and Ogreid D: Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer 79: 91-95, 1998.
72. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG and Choppin J: Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 160: 328-333, 1998.
73. Mandruzzato S, Brasseur F, Andry G, Boon T and van der Bruggen P: A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 186: 785-793, 1997.
74. Disis ML and Cheever MA: HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71: 343-371, 1997.
75. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I and Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810-11813, 1995.
76. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T and Coulie PG: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6: 199-208, 1997.
77. + melanoma. Int Immunol 5: 1501-1508, 1993.
78. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VJ, Lombard LA, Gray GS and Nadler LM: Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909-911, 1993.
79. Freeman GJ, Boussiotis VA, Amimanthan A, Bernstein GM, Kc XY, Renncrt PD, Gray GS, Gribben JG and Nadler LM: B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of 1L-4. Immunity 2: 523-532, 1995.
80. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ and Nadler LM: Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 84: 3261-3282, 1994.
81. Liu Y: Is Ctla-4 a necative regulator for T-cell activation. Immunol Today 18:569-572, 1997.
82. Duhring C, Angman L, Spagnoli G and Lanzavecchia A: T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfectcd with a B7 retroviral vector. Int J Cancer 57: 754-759, 1994.
83. Townsend SE, Su FW, Atherton JM and Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54: 6477-6483, 1994.
84. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153: 421-428, 1994.
85. Denfeld RW, Dietrich A, Wuttig C, Tanczos E, Weiss JM, Vanscheidt W, Schopf E and Simon JC: In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int J Cancer 62: 259-265, 1995.
86. Fenton RT, Sznol M, Luster DG, Taub DD and Longo DL: A phase I trial of B7-transfected parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. Hum Gene Ther 6: 87-106, 1995.
87. Dummer R, Yue F-Y, Pavlovic J, Geertscn R, Döring C, Moelling K and Burg G: Immune stimulatory potential of B7-1 and B7-2 retrovirally transduced melanoma cells: suppression by IL-10. Br J Cancer 77: 1413-1419, 1998.
88. Sule-Suso J, Arienti F, Melani C, Colombo MP and Parmiani G: A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and alloseneic lymphocytes. Eur J Immunol 25: 2737-2742, 1995.
89. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N and Glimcher LH: B7-1 and B7-2 costimulatory molecules activate differentially theTh1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80: 707-718, 1995.
90. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D and Azuma M: CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 154: 97-105, 1995.
91. Becker JC and Bröcker EB: Lymphocyte-melanoma interaction: role of surface molecules. Recent Results Cancer Res 139: 205-214, 1995.
92. Scheibenbogen C, Keilholz U, Meuer S, Dengler T, Tilgen W and Hunstein W: Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines. Int J Cancer 54: 494-498, 1993.
93. Becker JC, Dummer R, Hartmann AA, Burg G and Schmidt RE: Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gammruand tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 147: 4398-4401, 1991.
94. Dummer R, Sigg-Zemann S, Kaltoft K, Muletta S, Meyer J and Burg G: Various cytokines modulate ICAM-1 shedding from melanoma and CTCL-derived cell lines: inverse regulation of ICAM-1 shedding in a Sezary cell line by interferon-gamma. Dermatology 189: 120-124, 1994.
95. Dietrich A, Tanczos E, Vanscheidt W, Schopf E and Simon JC: High CD44 surface expression on primary tumours of malicnant melanoma correlates with increased mctastatic risk and reduced survival. Eur J Cancer 33: 926-930, 1997.
96. Schadendorf D, Diehl S, Zuberbie T, Schadendorf C and Henz BM: Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 192: 89-93, 1996.
97. Ravindranath MH, Amiri AA, Bauer PM, Kelley MC, Essner R and Morion DL: Endothelial-selectin ligands sialyl Lcwis(x) and sialyl Lcwis(a) are differentiation antigens immunogcnic in human melanoma. Cancer 79: 1686-1697, 1997.
98. Fiorentino DF, Bond MW and Mosmann TR: Two types of mouse T-hclper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170: 2081-2095, 1989.
99. Taga K and Tosato G: IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148: 1143-1148, 1992.
100. O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Hugo H, Barbis D, Stall A, Cupp J, Moore K, Whitmore A, Arnoid L, Haughton G and Howard M: Production of cytokines by mouse B cells: B lymphomas and normal B cells produce IL-10. Int Immunol 2: 821-827, 1990.
101. Enk AH and Katz SI: Identification and induction of keratinocyte-dcrived IL-10. J Immunol 149: 92-95, 1992.
102. Fiorcntino DF, Zlotnik A, Vieira P, Mosmann TR, Howard W, Moore KW and O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444-3451, 1991.
103. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T and Bröcker EB: Elevated serum levels of interleukin-10 in patients with metastatic malicnant melanoma. Melanoma Res 5: 67-68, 1995.
104. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S and Burg G: Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 71: 630-637, 1997.
105. Dummer W, Bastian BC, Ernst N, Schänzle C, Schwaaf A and Bröcker EB: Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 66: 607-610, 1996.
106. + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150:4754-4765, 1993.
107. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG and Kicssling R: Interleukin 10 pretreatmcnt protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180:2371-2376, 1994.
108. Haake AR and Polakowska RR: Pathways to programmed cell death: apoptosis and the skin. Curr Opin Dermatol 4: 247-255, 1997.
109. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J and Tschopp J: Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366, 1996.